The gradual evolution of pharmacogenomics has shed light on the genetic basis for inter-
individual drug response variations across diverse populations. This study aimed to identify …

Tacrolimus (TAC) is the backbone of an immunosuppressive drug used in most solid organ
transplant recipients. A single nucleotide polymorphism (SNP) at position 6986G> A in …

While CYP3A5 polymorphisms are used to predict the initial dosage of tacrolimus therapy,
the predictive capability of genetic information for dosing at early stage post-renal …

Background: Tacrolimus, a critical dose drug, is widely used in transplantation. Knowing the
contribution of genetic factors, which significantly influence tacrolimus variability, is …

Tacrolimus is metabolized by cytochrome P450 3A (CYP3A) and is susceptible to
interactions with the CYP3A and P‐glycoprotein inducer St. John's Wort (SJW). CYP3A …

Aims The population pharmacokinetic (PPK) model-based machine learning (ML) approach
offers a novel perspective on individual concentration prediction. This study aimed to …

The objective of this study was to assess the effect of the very low dosage of diltiazem on
tacrolimus exposure during the first week post-kidney transplantation, among cytochrome …

Background Genetic polymorphism is an important factor that influences tacrolimus
concentrations and has the potential to predict the optimal dosage of tacrolimus in …

Preventing rejection is a major challenge in transplantation medicine, even when using
pluripotent stem cell-derived grafts. In iPS cell (iPSC)-based transplantation, to reduce the …

Background Dosage quantities of tacrolimus (TAC) vary according to cytochrome P450 3A5
(CYP3A5) genotype. Genotyping is expected to optimize the response to TAC response and …